Ghent University Academic Bibliography

Advanced

Time to next anti-lymphoma therapy (TTNT) and treatment-free interval (TFI) with bortezomib-rituximab (VCR) vs rituximab® in patients (PTS) with relapsed follicular lymphoma (FL)

E Kimby, A Scheliga, J Mayer, Fritz Offner UGent, A Teixeira, K Kuliczkowski, AM Liberati, CY Okada, D Esseltine, P Theocharous, et al. (2011) ANNALS OF ONCOLOGY. 22(suppl. 4). p.187-187
Please use this url to cite or link to this publication:
author
organization
alternative title
Time to next anti-lymphoma therapy (TTNT) and treatment-free interval (TFI) with bortezomib-rituximab (VCR) vs rituximab (R) in patients (PTS) with relapsed follicular lymphoma (FL)
year
type
conference (meetingAbstract)
publication status
published
subject
in
ANNALS OF ONCOLOGY
Ann. Oncol.
volume
22
issue
suppl. 4
pages
187 - 187
conference name
11th International conference on Malignant Lymphoma
conference location
Lugano, Switzerland
conference start
2011-06-15
conference end
2011-06-18
Web of Science type
Meeting Abstract
Web of Science id
000291996300324
JCR category
ONCOLOGY
JCR impact factor
6.425 (2011)
JCR rank
17/190 (2011)
JCR quartile
1 (2011)
ISSN
0923-7534
language
English
UGent publication?
yes
classification
C3
id
2005591
handle
http://hdl.handle.net/1854/LU-2005591
date created
2012-01-27 10:20:38
date last changed
2016-12-19 15:37:18
@inproceedings{2005591,
  author       = {Kimby, E and Scheliga, A and Mayer, J and Offner, Fritz and Teixeira, A and Kuliczkowski, K and Liberati, AM and Okada, CY and Esseltine, D and Theocharous, P and Zhu, E and Van de Velde, H and Elsayed, YA and Coiffier, B},
  booktitle    = {ANNALS OF ONCOLOGY},
  issn         = {0923-7534},
  language     = {eng},
  location     = {Lugano, Switzerland},
  number       = {suppl. 4},
  pages        = {187--187},
  title        = {Time to next anti-lymphoma therapy (TTNT) and treatment-free interval (TFI) with bortezomib-rituximab (VCR) vs rituximab{\textregistered} in patients (PTS) with relapsed follicular lymphoma (FL)},
  volume       = {22},
  year         = {2011},
}

Chicago
Kimby, E, A Scheliga, J Mayer, Fritz Offner, A Teixeira, K Kuliczkowski, AM Liberati, et al. 2011. “Time to Next Anti-lymphoma Therapy (TTNT) and Treatment-free Interval (TFI) with Bortezomib-rituximab (VCR) Vs Rituximab® in Patients (PTS) with Relapsed Follicular Lymphoma (FL).” In Annals of Oncology, 22:187–187.
APA
Kimby, E., Scheliga, A., Mayer, J., Offner, F., Teixeira, A., Kuliczkowski, K., Liberati, A., et al. (2011). Time to next anti-lymphoma therapy (TTNT) and treatment-free interval (TFI) with bortezomib-rituximab (VCR) vs rituximab® in patients (PTS) with relapsed follicular lymphoma (FL). ANNALS OF ONCOLOGY (Vol. 22, pp. 187–187). Presented at the 11th International conference on Malignant Lymphoma.
Vancouver
1.
Kimby E, Scheliga A, Mayer J, Offner F, Teixeira A, Kuliczkowski K, et al. Time to next anti-lymphoma therapy (TTNT) and treatment-free interval (TFI) with bortezomib-rituximab (VCR) vs rituximab® in patients (PTS) with relapsed follicular lymphoma (FL). ANNALS OF ONCOLOGY. 2011. p. 187–187.
MLA
Kimby, E, A Scheliga, J Mayer, et al. “Time to Next Anti-lymphoma Therapy (TTNT) and Treatment-free Interval (TFI) with Bortezomib-rituximab (VCR) Vs Rituximab® in Patients (PTS) with Relapsed Follicular Lymphoma (FL).” Annals of Oncology. Vol. 22. 2011. 187–187. Print.